Related Experiment Video
Updated: Jul 19, 2026

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting
Published on: January 12, 2018
Rising to the challenge of treating high-risk patients
1College of Medicine and Public Health, Ohio State University, 146 Means, 1654 Upham Dr, Columbus, OH 43210, USA. Guthrie.1@osu.edu
Insights
High-risk patients benefit from lower LDL-C goals. Rosuvastatin therapy effectively helps patients achieve these cholesterol targets, improving cardiovascular health outcomes.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) guidelines emphasize lowering low-density lipoprotein cholesterol (LDL-C) in high-risk patients.
- Major clinical trials confirm the benefit of LDL-C reduction below ATP III targets (<100 mg/dL) for high-risk individuals.
- An optional, more aggressive LDL-C goal (<70 mg/dL) was suggested in 2004 for very high-risk patients, including those with diabetes or metabolic syndrome.
Purpose of the Study:
- To evaluate the efficacy of rosuvastatin in achieving lower LDL-C goals compared to other statin monotherapies.
- To assess the effectiveness of rosuvastatin in helping high-risk patients attain ATP III LDL-C targets.
Main Methods:
- Analysis of recent large clinical trials comparing rosuvastatin with other statin monotherapies.
- Review of data from the MERCURY (Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy) trials.
Main Results:
- Rosuvastatin demonstrated greater LDL-C reduction compared to other statin monotherapies.
- A significantly higher percentage of patients achieved their ATP III LDL-C targets when switched to rosuvastatin.
- Rosuvastatin therapy improved goal attainment rates in high-risk patient populations.
Conclusions:
- Rosuvastatin is effective in achieving aggressive LDL-C targets for high-risk patients.
- Switching to rosuvastatin therapy can significantly improve cholesterol goal attainment.
- These findings support the use of rosuvastatin in managing hyperlipidemia and reducing cardiovascular risk.
Abstract:
Guidelines from the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) focus the need for the most intensive efforts to lower low-density lipoprotein cholesterol (LDL-C) in the patients at greatest risk of a major future clinical coronary heart disease event. Major clinical trials, such as Pravastatin or Atorvastatin Evaluation and Infection Therapy and the Heart Protection Study, demonstrated the value of lowering LDL-C levels in high-risk patients to well below the ATP III target of <100 mg/dL. In 2004, the NCEP writing group suggested that a more aggressive LDL-C goal of <70 mg/dL is an option when treating high-risk patients, particularly those with the presence of established cardiovascular disease plus major multiple risk factors (especially diabetes), severe and poorly controlled risk factors (ie, cigarette smoking), multiple criteria of the metabolic syndrome, or an acute coronary syndrome. With stricter targets, high-risk patients are less likely to achieve their cholesterol goals than lower risk patients. Recent large trials comparing rosuvastatin with other statin monotherapies have shown a greater LDL-C reduction and better attainment of goals with rosuvastatin. In addition, the MERCURY [Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy] trials demonstrate that switching to rosuvastatin significantly increased the percentage of patients who achieved their ATP III LDL-C targets.
Related Concept Videos
Introduction To Health Care Delivery System
The Institute of Medicine (IOM) advocates for a patient-centered, effective, safe, timely, equitable, and effective healthcare system. The National Priorities...
Ethical Issues
Ethical Concerns in Healthcare:
Patient-centered Care
Methods of Documentation VI: Case Management Model
For example, a patient with a chronic illness...
Treatment Resistent Cancers
Treatment Resistant Cancers
